INSP Inspire Medical Systems, Inc.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1609550 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.2%
TTM net income YoY126.0%
TTM EPS YoY129.5%
Revenue 3-yr CAGR15.6%
Net income 3-yr CAGR—
Margins
Gross margin86.2%
Operating margin1.8%
Net margin11.4%
FCF margin11.1%
EBITDA margin3.9%
Returns
ROE13.5%
ROA11.4%
ROIC (approx.)2.6%
Asset turnover1.00x
Leverage & solvency
Liabilities / assets13.2%
Debt / equity0.00x
Current ratio6.45x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $911.98M | $802.80M | $624.80M | $407.86M | $233.39M |
| Cost of revenue | $133.22M | $122.99M | $96.58M | $66.11M | $33.28M |
| Gross profit | $778.76M | $679.82M | $528.22M | $341.74M | $200.12M |
| R&D expense | $103.17M | $114.13M | $116.54M | $68.64M | $37.35M |
| SG&A expense | $624.64M | $529.61M | $451.96M | $320.69M | $202.62M |
| Operating income | $50.95M | $36.08M | -$40.27M | -$47.59M | -$39.85M |
| Interest expense | $137,000 | $22,000 | $0 | $1.68M | $2.13M |
| Pretax income | $65.70M | $58.45M | -$19.91M | -$44.27M | -$41.97M |
| Income tax | -$79.72M | $4.94M | $1.25M | $613,000 | $72,000 |
| Net income | $145.42M | $53.51M | -$21.15M | -$44.88M | -$42.04M |
| EBITDA | $64.91M | $42.63M | -$37.42M | -$45.73M | -$38.63M |
| EPS (basic) | 4.95 | 1.80 | -0.72 | -1.60 | -1.54 |
| EPS (diluted) | 4.89 | 1.75 | -0.72 | -1.60 | -1.54 |
| Weighted avg. shares (diluted) | 29.76M | 30.54M | 29.30M | 28.07M | 27.26M |
| Balance sheet | |||||
| Cash & equivalents | $104.81M | $150.15M | $185.54M | $441.59M | $214.47M |
| Short-term investments | $203.46M | $295.40M | $274.84M | $9.82M | $0 |
| Receivables | $119.69M | $93.07M | $89.88M | $61.23M | $34.18M |
| Inventory | $145.29M | $80.12M | $33.88M | $11.89M | $17.23M |
| Current assets | $583.65M | $630.81M | $593.74M | $530.03M | $268.54M |
| PP&E, net | $97.87M | $71.92M | $39.98M | $17.25M | $8.49M |
| Total assets | $907.32M | $808.38M | $676.81M | $564.88M | $295.08M |
| Current liabilities | $96.06M | $88.50M | $78.11M | $61.19M | $41.31M |
| Long-term debt | — | — | — | — | $24.50M |
| Total debt | — | — | — | — | $24.50M |
| Total liabilities | $126.16M | $118.69M | $104.30M | $68.87M | $66.04M |
| Shareholders' equity | $781.16M | $689.70M | $572.51M | $496.01M | $229.05M |
| Net debt | — | — | — | — | -$189.97M |
| Shares outstanding | 28.58M | 29.74M | 29.56M | 29.01M | 27.42M |
| Cash flow statement | |||||
| Operating cash flow | $116.98M | $130.25M | $24.65M | $11.57M | -$20.12M |
| Capital expenditure | $38.50M | $39.12M | $23.63M | $9.10M | $4.67M |
| Free cash flow | $78.48M | $91.12M | $1.02M | $2.47M | -$24.79M |
| Investing cash flow | $21.45M | -$113.12M | -$294.82M | -$19.60M | $29.14M |
| Financing cash flow | -$183.45M | -$52.39M | $13.95M | $235.08M | $14.95M |
| Depreciation & amortization | $13.96M | $6.55M | $2.85M | $1.86M | $1.22M |
| Stock-based compensation | $130.26M | $116.01M | $82.47M | $51.97M | $26.18M |
| Share buybacks | $175.02M | $0 | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.